Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 01 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

The U.S. Food and Drug Administration has issued a Complete Response Letter that Sentynl and Zydus must address to clarify the path forward for the drug's approval. The press release emphasizes Zydus's commitment to working with the FDA to resolve the issues raised and to pursue resubmission of the NDA promptly.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases